Report
EUR 12.94 For Business Accounts Only

Increased risk weighs on NOTRE DAME, penalising its rating down to Neutral

The independent financial analyst theScreener just lowered the general evaluation of NOTRE DAME (BR), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as moderately risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Neutral. As of the analysis date December 21, 2021, the closing price was BRL 65.16 and its target price was estimated at BRL 55.12.
Underlying
Notre Dame Intermedica Participacoes SA

Notre Dame Intermedica Participacoes SA (Notre Dame), formerly known as BCBH Participacoes SA, is a Brazil-based company specialized in the healthcare industry. The Company operates as the holding company of the NotreDame Intermedica Group. Notre Dame has offices in Sao Paulo, Rio de Janeiro, Jundai, Campinas, Sorocaba and Baixada Santista and through its subsidiaries offers different medical services in Brazil. The Company owns more than 15 hospitals, more than 20 emergency rooms, more than 10 units of preventive medicine and more than 65 clinical centers. Notre Dame through its subsidiaries offers health services; dental services, which includes dental plans, preventive dentistry and online contact, and other specialized services as child surgery or occupational health.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch